Foundayo (Orforglipron) Approval Marks the Beginning of the Oral GLP-1 Era for Obesity Treatment
1. The FDA approved orforglipron (Foundayo) on April 1, 2026, making it the first non-peptide oral GLP-1 receptor agonist cleared ...
1. The FDA approved orforglipron (Foundayo) on April 1, 2026, making it the first non-peptide oral GLP-1 receptor agonist cleared ...
Diet Quality and Dementia Risk in Older Adults With Alzheimer Pathology 1. Greater adherence to a dietary pattern with lower ...
1. In this randomized trial, a comprehensive telehealth program produced modest but non-significant improvements in glycemic control compared with self-monitoring ...
1. In this randomized controlled trial, tirzepatide produced substantially greater reductions in HbA1c, body weight, waist circumference, and BMI than ...
Electronic Intervention for Patient-Managed Benzodiazepine Tapering 1. An electronic intervention promoting self-management of benzodiazepine cessation significantly increased the chances of ...
1. In hospitalized adults with coronavirus disease 2019 (COVID-19) and no structural heart disease, cardiac arrhythmias were common and were ...
1. Smoking and prior acute pancreatitis attacks independently predict poor glycaemic control in patients with post-chronic pancreatitis diabetes (PPDM-C). 2. ...
Glycaemic control and influencing factors among patients with post-chronic pancreatitis diabetes mellitus in China: a retrospective cross-sectional study 1. Smoking ...
1. In this prospective cohort study, an artificial intelligence tool was used to segment magnetic resonance imaging scans into body ...
1. On September 24, 2025, researchers reported that an AI bandage called a-Heal sped wound healing by 25 percent in ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.